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Aim
To evaluate the efficacy, toxicity, overall survival and
response of Gefitinib in previously untreated patients of
metastatic NSCLC with EGFR mutation.
Methods
60 patients with metastatic, non-small-cell lung cancer
and EGFR mutations who had not previously received
chemotherapy were randomly assigned to receive Gefitinib
250 mg orally daily or carboplatin -paclitaxel. The primary
end point was progression-free survival; secondary end
points included overall survival, response rate, and toxic
effects.
Results
The progression free survival was significanly longer in
Gefitinb group than in standard chemotherapy group.
The Gefitinib group had significantly longer median
progression free survival (10 months versus 5 months)
as well as higher response rates (70% versus 30%). The
median overall survival was 30 months in Gefitinib
group and 24 months in chemotherapy group. The most
common adverse events in Gefitinib group were rash
and elevated aminotransferase levels.
Conclusions
First-line Gefitinib for patients with advanced non-
small-cell lung cancer who were selected on the basis of
EGFR mutations improved progression-free survival,
with acceptable toxicity, as compared with standard
chemotherapy.
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